Hong Kong · Delayed Price · Currency is HKD Keymed Biosciences Statistics
Total Valuation
HKG:2162 has a market cap or net worth of HKD 23.45 billion. The enterprise value is 20.53 billion.
| Market Cap | 23.45B |
| Enterprise Value | 20.53B |
Important Dates
The next estimated earnings date is Friday, November 20, 2026.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2162 has 294.60 million shares outstanding. The number of shares has increased by 8.21% in one year.
| Current Share Class | 294.60M |
| Shares Outstanding | 294.60M |
| Shares Change (YoY) | +8.21% |
| Shares Change (QoQ) | +0.93% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 37.73% |
| Float | 219.45M |
Valuation Ratios
The trailing PE ratio is 25.41 and the forward PE ratio is 48.96.
| PE Ratio | 25.41 |
| Forward PE | 48.96 |
| PS Ratio | 24.34 |
| PB Ratio | 5.07 |
| P/TBV Ratio | 5.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 22.99 |
| EV / Sales | 21.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.83, with a Debt / Equity ratio of 0.17.
| Current Ratio | 4.83 |
| Quick Ratio | 4.21 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.67 |
| Interest Coverage | -42.93 |
Financial Efficiency
Return on equity (ROE) is 21.49% and return on invested capital (ROIC) is -33.51%.
| Return on Equity (ROE) | 21.49% |
| Return on Assets (ROA) | -8.24% |
| Return on Invested Capital (ROIC) | -33.51% |
| Return on Capital Employed (ROCE) | -14.00% |
| Weighted Average Cost of Capital (WACC) | 3.44% |
| Revenue Per Employee | 544,998 |
| Profits Per Employee | 505,179 |
| Employee Count | 1,768 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0.87 |
Taxes
In the past 12 months, HKG:2162 has paid 333.52 million in taxes.
| Income Tax | 333.52M |
| Effective Tax Rate | 27.18% |
Stock Price Statistics
The stock price has increased by +10.20% in the last 52 weeks. The beta is -0.14, so HKG:2162's price volatility has been lower than the market average.
| Beta (5Y) | -0.14 |
| 52-Week Price Change | +10.20% |
| 50-Day Moving Average | 77.70 |
| 200-Day Moving Average | 66.46 |
| Relative Strength Index (RSI) | 58.34 |
| Average Volume (20 Days) | 1,796,952 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2162 had revenue of HKD 963.56 million and earned 893.16 million in profits. Earnings per share was 3.13.
| Revenue | 963.56M |
| Gross Profit | 762.08M |
| Operating Income | -784.23M |
| Pretax Income | 1.23B |
| Net Income | 893.16M |
| EBITDA | -695.90M |
| EBIT | -784.23M |
| Earnings Per Share (EPS) | 3.13 |
Balance Sheet
The company has 3.73 billion in cash and 804.31 million in debt, with a net cash position of 2.92 billion or 9.92 per share.
| Cash & Cash Equivalents | 3.73B |
| Total Debt | 804.31M |
| Net Cash | 2.92B |
| Net Cash Per Share | 9.92 |
| Equity (Book Value) | 4.63B |
| Book Value Per Share | 15.70 |
| Working Capital | 3.61B |
Cash Flow
In the last 12 months, operating cash flow was -906.54 million and capital expenditures -301.53 million, giving a free cash flow of -1.21 billion.
| Operating Cash Flow | -906.54M |
| Capital Expenditures | -301.53M |
| Depreciation & Amortization | 89.54M |
| Net Borrowing | -215.26M |
| Free Cash Flow | -1.21B |
| FCF Per Share | -4.10 |
Margins
Gross margin is 79.09%, with operating and profit margins of -81.39% and 92.69%.
| Gross Margin | 79.09% |
| Operating Margin | -81.39% |
| Pretax Margin | 127.33% |
| Profit Margin | 92.69% |
| EBITDA Margin | -72.22% |
| EBIT Margin | -81.39% |
| FCF Margin | n/a |
Dividends & Yields
HKG:2162 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.21% |
| Shareholder Yield | -8.21% |
| Earnings Yield | 3.81% |
| FCF Yield | -5.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for HKG:2162 is 103.88, which is 27.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 103.88 |
| Price Target Difference | 27.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 60.15% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HKG:2162 has an Altman Z-Score of 4.98 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.98 |
| Piotroski F-Score | 3 |